Evidence analysisNovember 21, 2026Health & Science
Medical device makers have gotten worse at disclosing when their products harm people, new study finds. The FDA let them.

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
A recent peer-reviewed study published in The BMJ and reported by the International Consortium of Investigative Journalists (ICIJ) reveals a decline in transparency regarding adverse events associated with medical devices in the United States. The study analyzed 6,303 adverse event reports submitted between July 2019 and June 2025 under FDA summary reporting exemptions and found substantial underreporting and inaccuracy in these reports.
The U.S. Food and Drug Administration (FDA) previously allowed medical device manufacturers to submit incident reports via an alternative summary reporting program—in which quarterly spreadsheets replaced individual case reports—resulting in concealed serious injuries and deaths. Officially, this program was ended in 2019 to improve public transparency. However, the study uncovered that the FDA continued permitting summary reporting through exemptions that were not publicly disclosed.
Key findings include:
- Summary reports frequently contained incomplete, inaccurate, or delayed information.
- 57% of reports described an adverse event without identifying the specific device or user problem.
- 38% of reports acknowledged insufficient information regarding the device problem.
- 11% of reports wrongly indicated they contained only one adverse event, leading to an undercount of nearly 12,000 events.
- Most adverse events (over 90%) related to high-risk (Class 3) cardiac devices.
The study’s analysis also highlighted that nine of the thirteen devices benefitting from summary reporting exemptions experienced recalls, possibly delayed by the obscured nature of the reports.
What the source claims
ICIJ and the study’s co-author, Madris Kinard, a former FDA official, argue that the FDA’s continued allowance of summary reporting exemptions undermines patient safety by obstructing timely and accurate identification of safety signals related to medical devices. They emphasize that this data opacity impairs the ability of clinicians, regulators, researchers, and the public to detect patterns of harm.
An example underscoring this issue includes a summary report logging 4,445 deaths linked to a heart implant designed to reduce stroke risk, with a note that “multiple event terms may apply to a single patient,” which Kinard remarks is misleading since a patient cannot die more than once. The ongoing reliance on summary reporting, according to the source, leads to an underestimation of risk and can delay device recalls.
The source also suggests that companies may have incentives to underreport or obscure adverse events. A related investigation by The Boston Globe was cited, highlighting a cardiac implant manufacturer that promoted a device widely despite questions about its efficacy compared to standard treatments and concerns about expanded use beyond approved patient groups.
What may be missing from the usual framing
While the source outlines failures in data transparency and regulatory oversight, it does not fully explore the FDA’s rationale or potential challenges in managing large volumes of adverse event data. For example, the extent to which summary reporting exemptions may have been intended to reduce administrative burden or streamline reporting processes is not detailed.
Moreover, the impact on manufacturers’ compliance costs and resource allocation is not discussed, which could contextualize their reporting behaviors. There is insufficient information regarding whether efforts are underway within the FDA or industry to improve reporting accuracy or to phase out exemptions officially.
Finally, stakeholder perspectives beyond critics and investigative journalists—such as patient advocacy groups, industry representatives, or FDA officials—are not substantially represented, limiting a holistic understanding of incentives and constraints.
Competing evidence or uncertainty
Evidence is insufficient to confirm whether summary reporting exemptions were ever publicly justified by the FDA beyond internal regulatory discussions. The actual degree of causation between reporting deficiencies and delays in recalling devices remains uncertain without detailed timelines and regulatory decision data.
The source cites a very specific focus on cardiac devices, particularly Class 3 devices, raising questions about how generalizable these findings are across different device categories or medical contexts. There is also ambiguity about the true scale of underreported adverse events, given that aggregate figures do not distinguish between duplicated reports and unique cases.
The source relies heavily on Freedom of Information Act requests and investigative data which may not capture the full scope of regulatory oversight or manufacturer internal controls. More comprehensive data and independent regulatory audits would be needed to confirm systemic underreporting and its impact.
Why it matters
Medical devices, especially those classified as high-risk (Class 3), have direct and significant implications for patient health and safety. Reliable reporting of adverse events is vital for early detection of device problems and timely interventions, including recalls or safety communication. When manufacturers provide incomplete or inaccurate data and the FDA does not strictly enforce transparent reporting, patients may be exposed to higher risks without appropriate awareness or protection.
Lack of transparency can erode trust in regulatory systems and impede medical research by limiting datasets available for clinical analysis and safety evaluations. Understanding the limitations and vulnerabilities in adverse event reporting helps inform debates on regulatory reform, accountability, and patient rights.
What to verify next
- Confirm through official FDA communications or documents whether the exemptions to summary reporting were formally issued and on what grounds.
- Investigate if internal FDA or external oversight entities have responded or initiated changes addressing the issues highlighted in the study.
- Compare reporting quality and outcomes for devices not covered by summary reporting exemptions to assess differences in transparency and safety signals.
- Examine patient advocacy and clinical stakeholder assessments of the impact these reporting practices have had on patient safety and clinical decision-making.
- Monitor additional peer-reviewed research and regulatory audits that either corroborate or contest the scale of underreporting and delayed recalls.
Readers interested in a fuller understanding of this topic should consult the original ICIJ report and the associated study in The BMJ for comprehensive details and source materials.
Source & verification
Primary source: ICIJ · November 20, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

US Tries but Fails to Dilute UN Human Rights Resolutions
US Attempts to Weaken UN Human Rights Resolutions: An Evidence Review What is established In late 2026, during sessions of the United Nations General…

EMA/PE/0000181364
What is established The European Medicines Agency (EMA) has granted a decision regarding a paediatric investigation plan (PIP) for vosoritide as of 8 August…

EMA/PE/0000228795
Evidence Dossier: EMA Paediatric Investigation Plan for Ambrisentan/Tadalafil What is established The European Medicines Agency (EMA) has officially adopted a paediatric investigation plan (PIP)…